Muna Therapeutics appoints Dr. Niels Plath as Chief Scientific Officer
Brings more than 15 years of CNS drug discovery and development experience
Copenhagen, Denmark and Boston, US, 1st November 2021 – Muna Therapeutics (“Muna”), pioneering the development of novel, first-in-class small molecule therapeutics for neurodegenerative diseases, today announces the appointment of Dr. Niels Plath as Chief Scientific Officer.
